- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03380728
Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial
March 21, 2023 updated by: Rafael Guimarães dos Santos, University of Sao Paulo
Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: the First Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial
Approximately 5% of the world's adult population has some alcohol-related disorder, which in addition is associated with 3% of all deaths in the world.
In Brazil, harmful use and dependence on alcohol reach about 10% of the population, with alcohol being one of the main factors of disease and mortality.
Although the medications currently used have some efficacy, the adverse effects and relatively long time of treatment are factors that may reduce patients' motivation to continue taking the medication correctly.
Therefore, it is necessary to conduct research with new drugs for the treatment of alcoholism.
Ibogaine is an alkaloid present in the bush Tabernanthe iboga (iboga), a plant from Central Africa traditionally used in countries such as Gabon and Cameroon.
Animal studies and case series suggest that one or a few doses of ibogaine significantly reduce withdrawal symptoms and the intensity of use of various drugs, including opioids, psychostimulants, and alcohol.
However, there are no controlled clinical studies that have explored these effects.
The aim of the present study is to evaluate the safety, tolerability and efficacy of increasing doses of ibogaine in 12 alcoholic patients.
Each patient will be hospitalized for 20 days and receive 3 increasing doses of ibogaine.
The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design.
If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly.
The volunteers will also be evaluated 7, 14 and 21 days and 1, 3, 6 and 12 months after leaving the hospital to monitor the consumption of alcohol and other drugs.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rafael dos Santos, PhD
- Phone Number: 551636022703
- Email: banisteria@gmail.com
Study Locations
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazil, 14048900
- Ribeirão Preto Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Literate people
- Diagnosis of alcoholism assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-V)
- History of at least two previous failed treatments for alcoholism (with drug use and / or psychotherapy)
- Signing the Free and Informed Consent Form.
Exclusion Criteria:
- Presence of any psychiatric diagnosis (excluding alcohol / tobacco / nicotine abuse / dependence) assessed by the SCID-V
- Presence of clinical disease (especially cardiovascular and hepatic diseases), based on interview, physical and laboratory examination (hemogram and electrocardiogram, ECG)
- Absence of family or personal history of bipolar disorder and psychotic disorders
- Absence of recent symptoms of hypomania, mania or psychosis
- Non-literate people
- Pregnant or lactating women
- Recent use of illicit drugs (confirmed by examination in urine).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7
|
The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design.
If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
Other Names:
|
Experimental: Group 2
Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, placebo on day 7
|
The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design.
If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
Other Names:
|
Experimental: Group 3
Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, Ibogaine Hydrochloride 400 mg on day 7
|
The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design.
If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time without using alcohol
Time Frame: 0-1 month
|
Daily alcohol use
|
0-1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective effects
Time Frame: 0-12 hours
|
Acute and subacute subjective effects
|
0-12 hours
|
Cardiovascular effects
Time Frame: 0-72 hours
|
Electrocardiogram
|
0-72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Rafael dos Santos, PhD, Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo
- Study Director: Jaime Hallak, PhD, Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
- dos Santos RG, Bouso JC, Hallak JEC. The antiaddictive effects of ibogaine: A systematic literature review of human studies. Journal of Psychedelic Studies 1(1): 20-28, 2017.
- Clare W et al. Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report. Journal of Psychedelic Studies 1(1): 29-34.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 30, 2022
Primary Completion (Anticipated)
September 1, 2024
Study Completion (Anticipated)
December 1, 2024
Study Registration Dates
First Submitted
December 15, 2017
First Submitted That Met QC Criteria
December 20, 2017
First Posted (Actual)
December 21, 2017
Study Record Updates
Last Update Posted (Actual)
March 24, 2023
Last Update Submitted That Met QC Criteria
March 21, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcoholism
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Psychotropic Drugs
- Hallucinogens
- Ibogaine
Other Study ID Numbers
- 72938717.3.0000.5440
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholism
-
Yale UniversityCompletedFamilial Alcoholism VulnerabilityUnited States
-
Yonsei UniversityTerminated
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
University of Southern DenmarkActive, not recruitingGeneral Practice | Alcohol Abuse Alcoholism | Screening and Brief InterventionDenmark
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedEffects of Family History of Alcoholism and Sex on Alcohol AnalgesiaUnited States
-
Brown UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcoholic Liver Disease | Alcoholism,United States
-
Khoo Teck Puat HospitalNot yet recruitingEmergencies | Alcohol Use Disorder | Alcoholism and Alcohol Abuse
-
National Institute on Drug Abuse (NIDA)The Peter G. Dodge Foundation (PGDF)Completed
-
Virginia Commonwealth UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Yale University; University...CompletedAlcoholismUnited States
-
National Institute on Alcohol Abuse and Alcoholism...National Institute on Drug Abuse (NIDA); University of Rhode IslandTerminatedAlcoholismUnited States
Clinical Trials on Ibogaine Hydrochloride
-
DemeRx IB, Inc.Hammersmith Medicines Research; ERT: Clinical Trial Technology Solutions; MAC...Recruiting
-
International Center for Ethnobotanical Education...University of Sao Paulo; Universidad Autonoma de Madrid; University Rovira i... and other collaboratorsRecruitingOpioid Dependence | Drug Dependence | Drug Use DisordersSpain
-
Stanford UniversityActive, not recruitingHead Injury Trauma | Blast or Combat ExposureUnited States
-
Xijing Hospital of Digestive DiseasesCompleted
-
Xijing Hospital of Digestive DiseasesCompletedColorectal AdenomasChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.UnknownUremic PruritusChina
-
M.D. Anderson Cancer CenterWithdrawnMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdCompleted
-
EpygenixCompletedDravet SyndromeUnited States
-
Janssen Research & Development, LLCCompletedSexual Dysfunction, Physiological | EjaculationGermany, Spain, Portugal, Finland, Sweden, Austria